Form 4: Amylyx Pharmaceuticals CFO James M. Frates Reports Stock Sale to Cover Tax Obligations

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, reports the sale of shares to cover tax obligations related to vesting restricted stock units and a transfer of shares to a trust.

Summary

• On March 5, 2024, James M. Frates, the CFO of Amylyx Pharmaceuticals, sold 1,792 shares of common stock at a weighted average price of $18.7279 per share to cover tax withholding obligations related to the vesting of restricted stock units.
• The shares were sold in multiple transactions at prices ranging from $18.62 to $18.82.
• On February 26, 2024, Mr. Frates transferred 15,459 shares to the James M. Frates 2024 Grantor Retained Annuity Trust No. 1.
• Following the reported transactions, Mr. Frates directly owns 134,784 shares, and indirectly owns 15,459 shares through the James M. Frates 2024 Grantor Retained Annuity Trust No. 1 and 11,072 shares through the FRATES FAMILY 2013 IRREV TRUST.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but the sale of shares could be perceived neutrally or slightly negatively depending on the context.

Positives

• The sale of shares was to cover tax obligations related to vesting restricted stock units, which is a common practice.
• The transfer of shares to a trust is a standard estate planning activity.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates activity by the CFO of Amylyx Pharmaceuticals.

Stakeholder Impact

• The sale of shares by the CFO could have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased selling pressure.

Key Dates